Investigational drug · Phase 2
rhuGM-CSF
Also called: Granulocyte-Macrophage Colony-Stimulating Factor
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, Advanced Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "rhuGM-CSF"
First trial start
2023
Jul 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rhuGM-CSF", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Advanced Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Stomach and esophageal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "rhuGM-CSF" as an intervention, largest first.
- Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIVPivotal-lookingCompleted
Bionor Immuno ASIndustry
NCT00659789 · 137 participants · Start Aug 2008 · Primary completion Jun 2010
Drug: Vacc-4x; Sterile water · For: HIV I Infection
Sites: Los Angeles, California; Sacramento, California; Miami, Florida · 18 sites in all
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian CancerNot yet recruiting
Aston Sci. Inc.Industry
NCT05794659 · 98 participants (planned) · Start Jun 1, 2027 · Primary completion Dec 31, 2030
Drug: AST-201; Paclitaxel and 3 more · For: Advanced Ovarian Cancer
Sites: Seattle, Washington
- Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast CancerActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT02157051 · 42 participants · Start Jun 2015 · Primary completion Nov 25, 2022
Drug: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine · For: HER2 Negative Breast Carcinoma; Recurrent Breast Carcinoma; Stage IIIA Breast Cancer and 4 more
Sites: Seattle, Washington
Bionor Immuno ASIndustry
NCT01704781 · 36 participants · Start Sep 2012 · Primary completion Aug 2014
Drug: Lenalidomide; Lenalidomide placebo and 2 more · For: HIV-1 Infection
Sites: Hamburg, Germany; Berlin, Germany; Cologne, Germany · 4 sites in all
The Cleveland ClinicAcademic, hospital or other
NCT00003490 · 30 participants (planned) · Start Oct 1998
Drug: sargramostim; cyclophosphamide and 2 more · For: Multiple Myeloma and Plasma Cell Neoplasm
Sites: Cleveland, Ohio
Bionor Immuno ASIndustry
NCT02092116 · 26 participants · Start Mar 2014 · Primary completion Aug 2015
Drug: Romidepsin; Vacc-4x and 1 more · For: HIV I Infection
Sites: Aarhus N, Denmark
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerActive, not recruiting
Aston Sci. Inc.Industry
NCT05771584 · 24 participants · Start Jul 4, 2023 · Primary completion Feb 9, 2027
Drug: AST-301; rhuGM-CSF · For: Gastric Cancer
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Tainan, Taiwan · 6 sites in all
Aston Sci. Inc.Industry
NCT04864418 · 22 participants · Start Jun 9, 2021 · Primary completion Nov 2, 2023
Drug: AST-021p · For: Advanced Cancer
Sites: Seoul, South Korea · 3 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000694 · 18 participants
Drug: Interferon alfa-2b; Zidovudine and 1 more · For: Sarcoma, Kaposi; HIV Infections
Sites: New York, New York
Aston Sci. Inc.Industry
NCT05163223 · 10 participants · Start Feb 28, 2022 · Primary completion May 31, 2024
Drug: AST-301(pNGVL3-hICD); rhuGM-CSF and 3 more · For: Breast Cancer
Sites: Chandler, Arizona; La Jolla, California; Tampa, Florida · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-tumor efficacy of oncolytic herpes simplex viruses constructed by synthetic genomics in a murine colorectal carcinoma model and in human tumor cell lines.
Xiao H, Yin Q, Hu H, et al. · Virology 2027
- Systematic engineering of Pichia pastoris for high-level production of recombinant human granulocyte-macrophage colony-stimulating factor.
Cheng Z, Gong K, Song Y, et al. · Bioresour Technol 2026
- In situ-activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy.
Wang XG, Huang YL, Shi XR, et al. · iScience 2026
- Hypersensitivity Pneumonitis with the Progression of Latent Autoimmune Pulmonary Alveolar Proteinosis after Steroid Treatment.
Arai T, Hirose M, Takimoto T, et al. · Intern Med 2026
- Topical platelet-derived growth factor and granulocyte-macrophage colony-stimulating factor in deep second-degree burn wounds in rats: An exploratory quantitative and histopathological comparison.
Hu Y, Tang Q, Huang X · J Tissue Viability 2026
- Prophylactic granulopoiesis-stimulating factors for people with solid tumors undergoing cancer treatment.
Ma M, Yang M, Wu Y, et al. · Cochrane Database Syst Rev 2026
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.